UNSPSC 51203201: Mycophenolate mofetil

This classification denotes an inosine monophosphate dehydrogenase inhibitor and immunosuppressant, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 9242ECW6R0. European Medicines Agency schedules Mycophenolate mofetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03360MIG. Mycophenolate mofetil generally arises in the molecular formula C23H31NO7. The term 'mycophenolate mofetil' is a United States Adopted Name designation.

Mycophenolate mofetil bears US NLM identifiers UMLS ID C0209368 and NCI Concept Code C1468. Most nations, for tariff and trade purposes, schedule mycophenolate mofetil under 29419000 and SITC 54139. SMILES: CC1=C(C(=C(C2=C1COC2=O)O)CC=C(C)CCC(=O)OCCN3CCOCC3)OC.

UNSPSC 51203201 Mycophenolate mofetil is a Commodity code covering a specific immunosuppressant pharmaceutical used in transplant and autoimmune disease management. The recent state and local opportunities associated with this code show little direct alignment with the nominal product — the sourced records document procurement of antibiotics (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) and emergency-response supplies (Naloxone, drug deactivation systems) rather than mycophenolate mofetil itself. The code appears to be applied inconsistently or used as a catch-all pharmaceutical acquisition vehicle in state and local systems. When state and local governments do procure under pharmaceutical warehouse and pharmaceutical supply codes in this family, they source through piggyback cooperative purchasing agreements and competitive IFB processes, often bundling multiple drug products into single contracts with negotiated pricing and multi-year renewal options.

The geographic activity shown in recent records spans Illinois (Illinois Department of Public Health) and Florida (Seminole County), though the pharmaceutical opportunities recorded here are not specific to mycophenolate mofetil acquisition. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for antibiotic supply, while Seminole County released an IFB in June 2026 for emergency-response pharmaceuticals with a July 26, 2026 response deadline. Neither opportunity directly targets the immunosuppressant indicated by the code number, suggesting that organizations evaluating pursuit under UNSPSC 51203201 should verify the actual pharmaceutical products in demand before investing in proposal development and confirm the code alignment with issuing agencies during the RFQ or pre-bid phase.